Literature DB >> 10844038

Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson's model: intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system.

D Kirik1, C Rosenblad, A Bjorklund, R J Mandel.   

Abstract

Previous studies have used recombinant adeno-associated viral (rAAV) vectors to deliver glial cell line-derived neurotrophic factor (GDNF) in the substantia nigra to protect the nigral dopamine (DA) neurons from 6-hydroxydopamine-induced damage. However, no regeneration or functional recovery was observed in these experiments. Here, we have used an rAAV-GDNF vector to express GDNF long-term (6 months) in either the nigral DA neurons themselves, in the striatal target cells, or in both of these structures. The results demonstrate that both nigral and striatal transduction provide significant protection of nigral DA neurons against the toxin-induced degeneration. However, only the rats receiving rAAV-GDNF in the striatum displayed behavioral recovery, accompanied by significant reinnervation of the lesioned striatum, which developed gradually over the first 4-5 months after the lesion. GDNF transgene expression was maintained at high levels throughout this period. These results provide evidence that rAAV is a highly efficient vector system for long-term expression of therapeutic proteins in the nigrostriatal system.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10844038      PMCID: PMC6772474     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  46 in total

1.  GDNF protection against 6-OHDA: time dependence and requirement for protein synthesis.

Authors:  C M Kearns; W A Cass; K Smoot; R Kryscio; D M Gash
Journal:  J Neurosci       Date:  1997-09-15       Impact factor: 6.167

2.  Complementary and overlapping expression of glial cell line-derived neurotrophic factor (GDNF), c-ret proto-oncogene, and GDNF receptor-alpha indicates multiple mechanisms of trophic actions in the adult rat CNS.

Authors:  M Trupp; N Belluardo; H Funakoshi; C F Ibáñez
Journal:  J Neurosci       Date:  1997-05-15       Impact factor: 6.167

3.  Unbiased stereological estimation of the total number of neurons in thesubdivisions of the rat hippocampus using the optical fractionator.

Authors:  M J West; L Slomianka; H J Gundersen
Journal:  Anat Rec       Date:  1991-12

4.  Differential and persistent expression patterns of CNS gene transfer by an adeno-associated virus (AAV) vector.

Authors:  T J McCown; X Xiao; J Li; G R Breese; R J Samulski
Journal:  Brain Res       Date:  1996-03-25       Impact factor: 3.252

5.  Self-inactivating lentiviral vectors with enhanced transgene expression as potential gene transfer system in Parkinson's disease.

Authors:  N Déglon; J L Tseng; J C Bensadoun; A D Zurn; Y Arsenijevic; L Pereira de Almeida; R Zufferey; D Trono; P Aebischer
Journal:  Hum Gene Ther       Date:  2000-01-01       Impact factor: 5.695

6.  In vivo protection of nigral dopamine neurons by lentiviral gene transfer of the novel GDNF-family member neublastin/artemin.

Authors:  C Rosenblad; M Grønborg; C Hansen; N Blom; M Meyer; J Johansen; L Dagø; D Kirik; U A Patel; C Lundberg; D Trono; A Björklund; T E Johansen
Journal:  Mol Cell Neurosci       Date:  2000-02       Impact factor: 4.314

7.  GDNF family ligands and receptors are differentially regulated after brain insults in the rat.

Authors:  Z Kokaia; M S Airaksinen; A Nanobashvili; E Larsson; E Kujamäki; O Lindvall; M Saarma
Journal:  Eur J Neurosci       Date:  1999-04       Impact factor: 3.386

8.  Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test.

Authors:  M Olsson; G Nikkhah; C Bentlage; A Björklund
Journal:  J Neurosci       Date:  1995-05       Impact factor: 6.167

9.  Rate of cell death in parkinsonism indicates active neuropathological process.

Authors:  P L McGeer; S Itagaki; H Akiyama; E G McGeer
Journal:  Ann Neurol       Date:  1988-10       Impact factor: 10.422

10.  Behavioral and cellular protection of rat dopaminergic neurons by an adenoviral vector encoding glial cell line-derived neurotrophic factor.

Authors:  D L Choi-Lundberg; Q Lin; T Schallert; D Crippens; B L Davidson; Y N Chang; Y L Chiang; J Qian; L Bardwaj; M C Bohn
Journal:  Exp Neurol       Date:  1998-12       Impact factor: 5.330

View more
  102 in total

1.  Functional regeneration in a rat Parkinson's model after intrastriatal grafts of glial cell line-derived neurotrophic factor and transforming growth factor beta1-expressing extra-adrenal chromaffin cells of the Zuckerkandl's organ.

Authors:  E F Espejo; M C Gonzalez-Albo; J P Moraes; F El Banoua; J A Flores; I Caraballo
Journal:  J Neurosci       Date:  2001-12-15       Impact factor: 6.167

2.  Reversal of motor impairments in parkinsonian rats by continuous intrastriatal delivery of L-dopa using rAAV-mediated gene transfer.

Authors:  Deniz Kirik; Biljana Georgievska; Corinna Burger; Christian Winkler; Nicholas Muzyczka; Ronald J Mandel; Anders Bjorklund
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-26       Impact factor: 11.205

Review 3.  Nanoparticles for retinal gene therapy.

Authors:  Shannon M Conley; Muna I Naash
Journal:  Prog Retin Eye Res       Date:  2010-05-07       Impact factor: 21.198

Review 4.  Neurorestoration.

Authors:  Mikko Airavaara; Merja H Voutilainen; Yun Wang; Barry Hoffer
Journal:  Parkinsonism Relat Disord       Date:  2012-01       Impact factor: 4.891

Review 5.  Anterograde transport of neurotrophic factors: possible therapeutic implications.

Authors:  Matteo Caleo; Maria Cristina Cenni
Journal:  Mol Neurobiol       Date:  2004-04       Impact factor: 5.590

Review 6.  Early diagnosis and therapy of Parkinson's disease: can disease progression be curbed?

Authors:  Sagar Kansara; Akash Trivedi; Sheng Chen; Joseph Jankovic; Weidong Le
Journal:  J Neural Transm (Vienna)       Date:  2012-06-26       Impact factor: 3.575

7.  Transgene expression in the striatum following intracerebral injections of DNA nanoparticles encoding for human glial cell line-derived neurotrophic factor.

Authors:  A M Fletcher; T H Kowalczyk; L Padegimas; M J Cooper; D M Yurek
Journal:  Neuroscience       Date:  2011-08-04       Impact factor: 3.590

8.  Novel Focused Ultrasound Gene Therapy Approach Noninvasively Restores Dopaminergic Neuron Function in a Rat Parkinson's Disease Model.

Authors:  Brian P Mead; Namho Kim; G Wilson Miller; David Hodges; Panagiotis Mastorakos; Alexander L Klibanov; James W Mandell; Jay Hirsh; Jung Soo Suk; Justin Hanes; Richard J Price
Journal:  Nano Lett       Date:  2017-05-18       Impact factor: 11.189

9.  Neuronal expression of the transcription factor Gli1 using the Talpha1 alpha-tubulin promoter is neuroprotective in an experimental model of Parkinson's disease.

Authors:  D Suwelack; A Hurtado-Lorenzo; E Millan; V Gonzalez-Nicolini; K Wawrowsky; P R Lowenstein; M G Castro
Journal:  Gene Ther       Date:  2004-12       Impact factor: 5.250

10.  Neuroprotective potential of pleiotrophin overexpression in the striatonigral pathway compared with overexpression in both the striatonigral and nigrostriatal pathways.

Authors:  S E Gombash; F P Manfredsson; R J Mandel; T J Collier; D L Fischer; C J Kemp; N M Kuhn; S L Wohlgenant; S M Fleming; C E Sortwell
Journal:  Gene Ther       Date:  2014-05-08       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.